Anti-CD19 CAR T cells co-expressing the PD-1/CD28 chimeric switch receptor were evaluated in a phase 1 clinical trial treating patients with relapsed/refractory DLBCL (151). Here, CD19 is linked to diffuse large B-cell lymphoma.